Brandi Roberts sold $123k of DFTX
Chief Financial Officer at Definium Therapeutics, Inc.. 3,377 shares at an average of $36.57, traded Sep 25, 2026, filed Sep 29, 2026.
Score components
- +22RoleCFO
- +10Trade size$123k at market
- 0Share of holdings soldSold 0.8% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-112058, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | SOpen-market sale Common Shares10b5-1 | -3,377 | $36.57 | $123k | 394,528 | 14 d ago |
Related signals
Other insiders at Definium Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $1.2M 31,550 shares | -1% | |
| 28Weak | Definium Therapeutics, Inc. | Mark Sullivan Chief Legal Officer | $514k 14,051 shares | -3% | |
| 20Weak | Definium Therapeutics, Inc. | Matthew T. Wiley Chief Commercial Officer | $113k 3,097 shares | -1% | |
| 26Weak | Definium Therapeutics, Inc. | Daniel Karlin Chief Medical Officer | $397k 10,853 shares | -1% | |
| 26Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $722k 19,023 shares | -1% | |
| 45Moderate | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $1.3M 29,208 shares | -3% | |
| 21Weak | Definium Therapeutics, Inc. | Matthew T. Wiley Chief Commercial Officer | $129k 2,867 shares | -2% | |
| 28Weak | Definium Therapeutics, Inc. | Brandi Roberts Chief Financial Officer | $136k 3,013 shares | -1% | |
| 27Weak | Definium Therapeutics, Inc. | Daniel Karlin Chief Medical Officer | $452k 10,035 shares | -2% | |
| 29Weak | Definium Therapeutics, Inc. | Mark Sullivan Chief Legal Officer | $586k 13,008 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.